Children with rare diseases
    deserve therapeutic answers

    Discover
    ORPHELIA Pharma

    Development of essential
    medicines in the field of rare
    pediatric diseases.
    Read more

    ORPHELIA Pharma’s mission

    Four key pillars :

    Latest news

    11 June 2024

    ORPHELIA Pharma to collaborate with Oscar Lambret clinical center to study KIZFIZO®, the first pediatric drinkable formulation of temozolomide, for the treatment of refractory or relapsed nephroblastoma (Wilms tumor)

    Read More >
    22 May 2024

    ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®

    Read More >
    18 April 2024

    Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin

    Read More >